Medical network - on March 14, March 13, in 43 medical equipment company, has 28 disclose earnings forecast in 2016. Among them, 18 companies net profit increase, decline in six, four uncertainty. The whole plate performance growth slowed markedly, while net profit growth of the company, but much smaller, increase business growth is very few. Under the background of increasingly stringent regulation, industry reshuffle will speed up.
Overall performance under pressure
Wind, according to the above 28 companies operating income in 2016 year-on-year growth of about 3% on average, net profit growth of about 5% on average.
In net profit increase of 18 companies, year-on-year growth in more than 30% of including treasure Wright, shares thereof, nine Ann medical, CDH innovation, Wan Dong medical, diving medical treatment, medical market, heart health, Dave. In addition, kelly, mike creatures, Europe PuKang net profit rose slightly. It is worth noting that the company's net profit more than from the denotative expansion and table, few rely on spontaneous growth.
Net profit fell by more than 20% of the company including YangPu important medical, sanxin medical, east, and three biological, qianshan mountain medicine machine, the state apparatus. For the cause of the decline in performance, the companies in the same reason: affected by the overall economic environment downward and industry policy, the pharmaceutical industry growth is slowing, pharmaceutical equipment demand, market competition is intense.
In the east of the lyophilizer important, large infusion equipment chutian science and technology, qianshan mountain medicine machine, solid Canaan technology of pharmaceutical equipment, poor performance as a whole. Important east is expected to achieve the business income is 1.3 billion yuan, fell 14.94% year on year; Net profit for 230 million yuan, fell 38.24% year on year. Qianshan mountain medicine machines expected revenue is 760 million yuan, up 39.28% from a year earlier. Net income of 43.7451 million yuan, down 26.81% year on year. Chutian science and technology is expected revenue is 1.126 billion yuan, up 15.55%; Net income of 155 million yuan, up 0.85% from a year earlier. Canaan technology is expected to achieve the business income is 300 million yuan, up 38.81% from a year earlier. Net profit of 62.2306 million yuan, up 20.94% from a year earlier.
Important reading results found that calendar year 2015, the east can achieve 1.5 billion yuan of business revenue and net profit of $380 million.
The boom of industry decline
Equipment manufacturing industry is important link in the production of drugs. For the boom of industry downturn, China pharmaceutical enterprise management association ming-de yu think, first of all, is the domestic equipment manufacturing level is low, only satisfy certain link, in many cases difficult to provide the whole production line production of form a complete set, high profit part is often overseas enterprises. Followed by the domestic pharmaceutical enterprise production management backwardness, insufficient consciousness of initiative to improve the production line to improve product quality production efficiency.
Important ming-de yu said: "east, chutian science and technology, qianshan mountain medicine machine performance have reached a peak around 2015, fallen considerably since 2016. The deep reason lies in the drug companies need to complete the GMP certification by the end of 2015, forcing drug firms investment of equipment on a large scale at this stage. As the time deadline, for the certification of enterprise in the input power greatly reduced, equipment company nature in trouble."
It is important to note that important east, chutian science and technology, qianshan mountain medicine machine belongs to the liquid preparation machinery, koren pharmaceutical, China resources double crane, with related company HuaRen pharmaceutical sales associate, the cause of the decline in the performance is under the background of strict resistance limit industry demand caused by shrinkage. And provide solid preparation equipment of Canaan technology still can maintain the steady growth of 20%, higher than that of the whole pharmaceutical industry growth. This shows that the boom of tablet, capsule market better than infusion products.
For the medical equipment industry, medical device manufacturing enterprise at present in China nearly 16000, similar products manufacturing enterprises are often up to a dozen, dozens or even hundreds of, and between enterprises have different production standards, the overall level is uneven. Since 2016, the state began to camp to increase in the pharmaceutical industry, medical consumable price of two votes, such as policy, these factors will hasten industry reshuffle.
Multidimensional choose investment targets
"The vast market of medical equipment, at the same time that there are many areas of a single market is small, to participate in the enterprise, market competition is intense. In terms of investment, looking for industry policy support, market space is large niche is especially important." Huatai securities medical researcher bright thought.
The first is the field of policy support. Localization of high-end medical equipment is the current policy direction of encouragement. "Made in China 2025", points out that the innovative ability of medical equipment and industrialization level must be raised, imaging equipment, medical robot, such as high performance medical device, the degradation of stent high value-added medical consumables, wearable, remote diagnosis and treatment, and other key mobile medical products is development. Since then, national food drug safety administration of supporting measures, conduct priority review of high-end medical devices.
Second are becoming an increasingly strict regulation, industry standardization of the company is expected to be the strong stronger. Since 2015, the state increased to examine the medical equipment production and circulation enterprises, and carry out the standardization system construction of medical equipment. Non-standard production and operation of enterprises is cleared out of the market gradually, and operating norms of leading enterprises will win more market share.
In addition, chronic disease management class equipment demand will erupt. Bright thought, an ageing population will lead to cardiovascular and diabetes, patients' health management and intelligent instrument needs huge guidelines. From the existing policy, equipment conform to the state classification diagnosis and treatment of chronic disease management reform direction. |
